Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 246 results for maternity

  1. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 4 June 2026.

  2. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 17 June 2026.

  3. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 18 June 2026.

  4. Antenatal and postnatal mental health: clinical management and service guidance (CG192)

    This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers depression, anxiety disorders, eating disorders, drug- and alcohol-use disorders and severe mental illness (such as psychosis, bipolar disorder and schizophrenia). It promotes early detection and good management of mental health problems to improve women’s quality of life during pregnancy and in the year after giving birth.

  5. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 18 June 2026.

  6. Why address health inequalities?

    Health inequalities can be experienced by people grouped by a range of different factors.

  7. Pregnancy and neonates: neonatal admissions (IND23)

    This indicator covers the proportion of births resulting in a neonatal unit admission. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG36

  8. Mortality: infant (IND283)

    This indicator covers infant Mortality. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  9. Donor milk banks: service operation (CG93)

    This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.

  10. Inducing labour (NG207)

    This guideline covers the circumstances for inducing labour, methods of induction, assessment, monitoring, pain relief and managing complications. It aims to improve advice and care for pregnant women who are thinking about or having induction of labour.

  11. NICE Funding Variation Request Consultation: methods / process manual consultation

    We are listening to your views on this NICE process and methods. Comments close 19 June 2026.

  12. Our benefits, rewards and work-life balance

    Our staff really enjoy working with us, thanks to our great package of rewards and benefits.

  13. Antenatal and postnatal mental health (QS115)

    This quality standard covers recognising, assessing and treating mental health problems in women planning, during or after pregnancy (up to a year after childbirth). It also covers the organisation of mental health services for women during and after pregnancy. It describes high-quality care in priority areas for improvement.

  14. Patient safety

    Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.

  15. Rare diseases (QS214)

    This quality standard covers diagnosing, managing and treating rare diseases in children, young people and adults. It describes high-quality care in priority areas for improvement.